NCT06513039 Evaluation of Erythropoietin on Alveolar Ridge Preservation
| NCT ID | NCT06513039 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Ain Shams University |
| Condition | Alveolar Bone Loss |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2025-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 15 participants in total. It began in 2024-01-01 with a primary completion date of 2025-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
regenerative materials would help in decreasing post-extraction resorption in sites indicated for placement of a conventional bridge or prosthetically driven implant. Erythropoietin (EPO) is a growth factor that promotes angiogenesis and bone regeneration by stimulating osteoblastic differentiation and by inhibiting osteoclastic resorption. Post-extraction alveolar ridge resorption creates morphological and volumetric changes. These changes can be considered of clinical value that may threaten the placement of a conventional bridge or an implant-supported crown. Atwood et al. \[1\] in a cephalometric study categorized factors influencing the rate of alveolar ridge resorption into 4 types: anatomic, metabolic, functional, and prosthetic. As stated by Tan et al. \[2\] in a systematic review of alveolar hard and soft tissue dimensional changes in humans post-extraction, they found that alveolar ridge resorption occurs to a greater extent in a horizontal direction than vertical. Therefore, alveolar ridge preservation (ARP) procedures were introduced in an attempt to prevent hard and soft tissue dimensional changes following extraction.
Eligibility Criteria
Inclusion Criteria: 1. Age range (18-40). 2. Hopeless teeth indicated for extraction such as root fractures, caries, internal root resorption, external root resorption, endodontic failures. 3. Systemically free patients using Cornell Medical Index-Health Questionnaire \[36\]. 4. Patients diagnosed with intact surrounding alveolar bone (socket type I) \[37\]. 5. Maxillary anterior teeth and/or premolars indicated for extraction. 6. Enough zone of keratinized tissue (≥2 mm). Exclusion Criteria: 1. Smokers 2. Occlusal trauma at the site of the graft 3. Pregnancy and lactation 4. Bad compliance with the plaque control instructions following initial therapy.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06513039 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Alveolar Bone Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06513039 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06513039 currently recruiting?
Yes, NCT06513039 is actively recruiting participants. Contact the research team at marwaelkassaby@dent.asu.edu.eg for enrollment information.
Where is the NCT06513039 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06513039 clinical trial?
NCT06513039 is sponsored by Ain Shams University. The trial plans to enroll 15 participants.